You have read all your free articles, to continue reading subscribe to read the rest of this content.
Aprea Therapeutics has announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for APR-246 in combination with azacitidine for the treatment of myelodysplastic syndromes (MDS) with a susceptible TP53 mutation. MDS represents a spectrum of hematopoieAlready a subscriber Login You have read all your free…
Saphnelo (anifrolumab-fnia) has been approved in the US for the treatment of adult patients with moderate to severe systemic lupus erythematosus (SLE) who are receiving standard therapy. This marks the first regulatory approval for a type I interferon (type I IFN) receptor antagonist and the onlyAlready a subscriber Login You…
Novo Nordisk has announced that it plans to invest more than 100 million euros in production facilities at its site in Chartres, France. The new facilities will be built on Novo Nordisk's existing 31,000 m2 site in Chartres, which produces a range of the company's insulin products as well as FleAlready…
AstraZeneca and Daiichi Sankyo’s Enhertu has been approved in the US for the treatment of adult patients with unresectable or metastatic HER2-positive breast cancer who have received a prior anti-HER2-based regimen either in the metastatic setting, or in the neoadjuvant or adjuvant setting and havAlready a subscriber Login You have…
